Deal-Ticker: Kellerhals Carrard represented Moderna in the inspection of the Control Committee of the National Council regarding the management of the COVID-19 pandemic

Kellerhals Carrard represented Moderna as it was heard as a third party in the inspection of the Control Committee of the National Council (CC-N) that was launched in May 2020 regarding the handling of the COVID-19 pandemic by the Federal Authorities. The final report of the CC-N was published on November 18, 2021. It concludes that the Federal Authorities made appropriate strategic decisions in quickly negotiating a contract with Moderna, which enabled fast and comprehensive access of Switzerland to the Moderna vaccine. The team was led by partners Dr. Claudia Götz Staehelin and Dr. Oliver M. Brupbacher and included partner Jean-Rodolphe Fiechter, associate Marlen Schultze and junior associate Nadja Fischer.

Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics with the potential to treat a wide range of diseases and conditions. Moderna's COVID-19 vaccine (Spikevax®) received temporary marketing authorization in Switzerland in January 2021.